S&P 500   3,961.70 (-0.05%)
DOW   33,712.24 (-0.20%)
QQQ   284.19 (+0.12%)
AAPL   144.29 (+1.15%)
MSFT   247.03 (-0.15%)
META   116.77 (+1.25%)
GOOGL   93.67 (-0.04%)
AMZN   89.36 (-1.10%)
TSLA   179.98 (+3.77%)
NVDA   172.71 (+0.59%)
NIO   12.85 (-4.18%)
BABA   92.15 (-2.15%)
AMD   69.57 (-1.28%)
T   19.21 (+0.47%)
MU   55.49 (+0.53%)
CGC   2.94 (-4.85%)
F   13.23 (+0.84%)
GE   82.27 (-1.63%)
DIS   93.94 (+1.50%)
AMC   5.86 (-3.46%)
PYPL   74.18 (-0.05%)
PFE   51.91 (+0.25%)
NFLX   325.29 (+4.84%)
S&P 500   3,961.70 (-0.05%)
DOW   33,712.24 (-0.20%)
QQQ   284.19 (+0.12%)
AAPL   144.29 (+1.15%)
MSFT   247.03 (-0.15%)
META   116.77 (+1.25%)
GOOGL   93.67 (-0.04%)
AMZN   89.36 (-1.10%)
TSLA   179.98 (+3.77%)
NVDA   172.71 (+0.59%)
NIO   12.85 (-4.18%)
BABA   92.15 (-2.15%)
AMD   69.57 (-1.28%)
T   19.21 (+0.47%)
MU   55.49 (+0.53%)
CGC   2.94 (-4.85%)
F   13.23 (+0.84%)
GE   82.27 (-1.63%)
DIS   93.94 (+1.50%)
AMC   5.86 (-3.46%)
PYPL   74.18 (-0.05%)
PFE   51.91 (+0.25%)
NFLX   325.29 (+4.84%)
S&P 500   3,961.70 (-0.05%)
DOW   33,712.24 (-0.20%)
QQQ   284.19 (+0.12%)
AAPL   144.29 (+1.15%)
MSFT   247.03 (-0.15%)
META   116.77 (+1.25%)
GOOGL   93.67 (-0.04%)
AMZN   89.36 (-1.10%)
TSLA   179.98 (+3.77%)
NVDA   172.71 (+0.59%)
NIO   12.85 (-4.18%)
BABA   92.15 (-2.15%)
AMD   69.57 (-1.28%)
T   19.21 (+0.47%)
MU   55.49 (+0.53%)
CGC   2.94 (-4.85%)
F   13.23 (+0.84%)
GE   82.27 (-1.63%)
DIS   93.94 (+1.50%)
AMC   5.86 (-3.46%)
PYPL   74.18 (-0.05%)
PFE   51.91 (+0.25%)
NFLX   325.29 (+4.84%)
S&P 500   3,961.70 (-0.05%)
DOW   33,712.24 (-0.20%)
QQQ   284.19 (+0.12%)
AAPL   144.29 (+1.15%)
MSFT   247.03 (-0.15%)
META   116.77 (+1.25%)
GOOGL   93.67 (-0.04%)
AMZN   89.36 (-1.10%)
TSLA   179.98 (+3.77%)
NVDA   172.71 (+0.59%)
NIO   12.85 (-4.18%)
BABA   92.15 (-2.15%)
AMD   69.57 (-1.28%)
T   19.21 (+0.47%)
MU   55.49 (+0.53%)
CGC   2.94 (-4.85%)
F   13.23 (+0.84%)
GE   82.27 (-1.63%)
DIS   93.94 (+1.50%)
AMC   5.86 (-3.46%)
PYPL   74.18 (-0.05%)
PFE   51.91 (+0.25%)
NFLX   325.29 (+4.84%)
NASDAQ:ABCL

AbCellera Biologics - ABCL Stock Forecast, Price & News

$10.64
-0.50 (-4.49%)
(As of 12/9/2022 01:34 PM ET)
Add
Compare
Today's Range
$10.60
$11.13
50-Day Range
$9.89
$14.52
52-Week Range
$5.42
$15.90
Volume
52,470 shs
Average Volume
2.08 million shs
Market Capitalization
$3.04 billion
P/E Ratio
13.47
Dividend Yield
N/A
Price Target
$28.50

AbCellera Biologics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
167.4% Upside
$28.50 Price Target
Short Interest
Bearish
9.18% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From $0.62 to ($0.35) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Medical Sector

531st out of 1,022 stocks

Pharmaceutical Preparations Industry

235th out of 499 stocks

ABCL stock logo

About AbCellera Biologics (NASDAQ:ABCL) Stock

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Receive ABCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbCellera Biologics and its competitors with MarketBeat's FREE daily newsletter.

ABCL Stock News Headlines

AbCellera Biologics (NASDAQ:ABCL) Shares Up 7%
FDA Pulls Emergency Use Authorization For Lilly's COVID-19 Antibody Drug
AbCellera Reports Q3 2022 Business Results
ABCL AbCellera Biologics Inc.
See More Headlines
Receive ABCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbCellera Biologics and its competitors with MarketBeat's FREE daily newsletter.

ABCL Company Calendar

Last Earnings
11/08/2021
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/23/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ABCL
Fax
N/A
Employees
386
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$28.50
High Stock Price Forecast
$40.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+167.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$153.46 million
Pretax Margin
58.89%

Debt

Sales & Book Value

Annual Sales
$375.20 million
Cash Flow
$0.58 per share
Book Value
$3.64 per share

Miscellaneous

Free Float
199,412,000
Market Cap
$3.04 billion
Optionable
Not Optionable
Beta
-0.42

Key Executives

  • Dr. Carl L.G. Hansen Ph.D. (Age 47)
    CEO, Pres & Chairperson
    Comp: $616.66k
  • Mr. Andrew  Booth M.B.A.Mr. Andrew Booth M.B.A. (Age 48)
    Chief Financial Officer
    Comp: $563.57k
  • Dr. Veronique  Lecault Ph.D.Dr. Veronique Lecault Ph.D. (Age 37)
    COO & Director
    Comp: $563.57k
  • Mr. Tryn T. Stimart Esq. (Age 52)
    J.D., Chief Legal Officer, Chief Compliance Officer & Corp. Sec.
    Comp: $563.8k
  • Dr. Ester Falconer Ph.D. (Age 47)
    Chief Technology Officer
  • Mr. Bo Barnhart Ph.D.
    Scientific Director
  • Ms. Tiffany Chiu B.Sc.
    Ph.D., VP of Communications
  • Mr. Murray McCutcheon Ph.D.
    VP of Corp. Devel.
  • Alexandra Weirich M.Sc.
    Mang. of Marketing & Communications
  • Caitlin Webster CIPD
    M.Sc., Sr. Mang. of People & Culture













ABCL Stock - Frequently Asked Questions

Should I buy or sell AbCellera Biologics stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbCellera Biologics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ABCL shares.
View ABCL analyst ratings
or view top-rated stocks.

What is AbCellera Biologics' stock price forecast for 2023?

7 Wall Street analysts have issued 1 year price targets for AbCellera Biologics' shares. Their ABCL share price forecasts range from $20.00 to $40.00. On average, they expect the company's share price to reach $28.50 in the next twelve months. This suggests a possible upside of 162.4% from the stock's current price.
View analysts price targets for ABCL
or view top-rated stocks among Wall Street analysts.

How have ABCL shares performed in 2022?

AbCellera Biologics' stock was trading at $14.30 on January 1st, 2022. Since then, ABCL stock has decreased by 24.1% and is now trading at $10.86.
View the best growth stocks for 2022 here
.

When is AbCellera Biologics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our ABCL earnings forecast
.

How were AbCellera Biologics' earnings last quarter?

AbCellera Biologics Inc. (NASDAQ:ABCL) issued its quarterly earnings data on Monday, November, 8th. The company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by $0.03. The firm earned $5.51 million during the quarter, compared to analysts' expectations of $10.51 million. AbCellera Biologics had a net margin of 41.17% and a trailing twelve-month return on equity of 21.15%.

When did AbCellera Biologics IPO?

(ABCL) raised $356 million in an initial public offering on Friday, December 11th 2020. The company issued 23,000,000 shares at $14.00-$17.00 per share. Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets acted as the underwriters for the IPO.

What is AbCellera Biologics' stock symbol?

AbCellera Biologics trades on the NASDAQ under the ticker symbol "ABCL."

Who are AbCellera Biologics' major shareholders?

AbCellera Biologics' stock is owned by a number of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (4.68%), BlackRock Inc. (4.39%), Credit Suisse AG (1.44%), Guardian Capital Advisors LP (1.31%), Lazard Asset Management LLC (1.15%) and State Street Corp (1.12%). Insiders that own company stock include Andrew Booth, Andrew Lo, Carl L G Hansen, Holdings Ltd Thermopylae, John Hamer, John S Montalbano, Michael R Hayden and Veronique Lecault.
View institutional ownership trends
.

How do I buy shares of AbCellera Biologics?

Shares of ABCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AbCellera Biologics' stock price today?

One share of ABCL stock can currently be purchased for approximately $10.86.

How much money does AbCellera Biologics make?

AbCellera Biologics (NASDAQ:ABCL) has a market capitalization of $3.11 billion and generates $375.20 million in revenue each year. The company earns $153.46 million in net income (profit) each year or $0.79 on an earnings per share basis.

How many employees does AbCellera Biologics have?

The company employs 386 workers across the globe.

How can I contact AbCellera Biologics?

The official website for the company is www.abcellera.com. The company can be reached via phone at 604 559 9905 or via email at ir@abcellera.com.

This page (NASDAQ:ABCL) was last updated on 12/9/2022 by MarketBeat.com Staff